Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

Company profile

Sanofi

Immunology + vaccines

SNY · Nasdaq · France

Share price · SNY

$39.92-3.24 (-7.51%) 3M

close as of 2026-10-02 · 24h delayed · vol 4.3M (1.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Research

See what was announced around each unusual move

Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.

Assets

(37 total)
37Total Assets
14Approved
7Phase 3 / Filed
16Phase 1–2 / Early
18Diseases
Quick filter:
Showing 37 of 37 assets
Target & Modality
Agalsidase beta(Fabrazyme)
Approved
Alpha-galactosidase A (GLA / α-Gal A)Protein / enzyme therapeutic
Fabry Disease
Approved
CD52Monoclonal antibody
Multiple Sclerosis
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
Approved
Microtubules (tubulin)Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
dupilumab(Dupixent)
Approved
IL-4R-alphaMonoclonal antibody
Atopic DermatitisAsthma
insulin glargine(Lantus / Toujeo)
Approved
Insulin receptor (basal)Peptide
Type 2 Diabetes
Approved
Insulin receptor (basal)Peptide
Type 2 Diabetes
Approved
CD38Monoclonal antibody
Multiple Myeloma
lixisenatide(Adlyxin / Lyxumia)
Approved
GLP-1 receptorPeptide
Type 2 Diabetes
Approved
CXCR4Small molecule
Multiple Myeloma
Approved
Insulin receptor (basal)Peptide
Type 2 Diabetes
Approved
IL-6 receptorMonoclonal antibody
Rheumatoid Arthritis
Approved
Dihydroorotate dehydrogenase (DHODH)Small molecule
Multiple Sclerosis
Approved
GABAergic neurotransmissionSmall molecule
Epilepsy
Ciclesonide (XRP1526)No recent activity
Phase 3
Glucocorticoid receptorSmall molecule
Asthma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Unlock with Research ↗
Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Unlock with Research ↗
Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Unlock with Research ↗
Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.